Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is radiofrequency ablation effective in patients with early-stage hepatocellular carcinoma and cirrhosis?

Nature Clinical Practice Oncology volume 2, pages 438–439 (2005)Cite this article

boxed-textLencioni R et al. (2005) Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 234: 961–967

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Dupuy DE and Goldberg SN (2001) Image-guided radiofrequency tumor ablation: challenges and opportunities—Part II. J Vasc Interv Radiol 12: 1135–1148

    Article  CAS  Google Scholar 

  2. Livraghi T et al. (1999) Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 210: 655–661

    Article  CAS  Google Scholar 

  3. Lau WY et al. (2003) Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann Surg 237: 171–179

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Livraghi T et al. (2000) Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology 214: 761–768

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Dr Jean-Francois Geschwind, Associate Professor and Director of Vascular and Interventional Radiology, Johns Hopkins Hospital, Baltimore, MD, USA.

Author information

Authors and Affiliations

  1. Director of Abdominal Intervention and Tumor Ablation and Director of the Minimally Invasive Tumor Therapy Laboratory at Beth Israel Deaconess Medical Center, and an Associate Professor of Radiology at Harvard University, Boston, MA, USA

    S Nahum Goldberg

Authors
  1. S Nahum Goldberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Nahum Goldberg.

Ethics declarations

Competing interests

Dr Goldberg receives sponsored research support and is on the advisory board of Valleylab, Boulder, CO, a manufacturer of radiofrequency ablation devices. He also receives research support from the NCI.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goldberg, S. Is radiofrequency ablation effective in patients with early-stage hepatocellular carcinoma and cirrhosis?. Nat Rev Clin Oncol 2, 438–439 (2005). https://doi.org/10.1038/ncponc0285

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0285

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing